12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 2,865,100 | $348,367,509 | +12% | 1.76% |
| 2. | VenBio Select Advisor Kurt Von Emster | 2,555,555 | $310,729,932 | 4.39% | |
| 3. | Casdin Capital Eli Casdin | 1,073,500 | $130,526,865 | 8.68% | |
| 4. | OrbiMed Advisors Samuel Isaly | 963,400 | $117,139,806 | +1% | 2.4% |
| 5. | Alkeon Capital Management Panayotis Takis Sparaggis | 853,845 | $103,819,013 | +35% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.66 | 5,648 | 284,034 | 2024-08-16 | Filing | ||
| $134.06 | 18,284 | 278,386 | 2024-08-16 | Filing | ||
| $133.07 | 13,106 | 260,102 | 2024-08-16 | Filing | ||
| $78.81 | 40,000 | Director | 140,000 | 2023-11-03 | Filing | |
| $78.81 | 10,000 | Director | 10,000 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $124.84 | 10,500 | 22,840 | 2024-12-12 | Filing | ||
| $125.55 | 1,636 | 5,880 | 2024-12-05 | Filing | ||
| $137.36 | 5,985 | 33,946 | 2024-08-30 | Filing | ||
| $164.52 | 2,549 | 17,129 | 2024-06-25 | Filing | ||
| $163.53 | 3,840 | 19,678 | 2024-06-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,191,986 | $1,360,833,548 | 0.02% | |
| 2. | 9,085,456 | $1,104,700,596 | 0.01% | |
| 3. | 8,697,137 | $1,057,482,090 | 0.19% | |
| 4. | 4,328,323 | $526,204,179 | 0.26% | |
| 5. | 4,069,864 | $494,854,764 | 0.01% |
News See All
Jim Cramer’s Lightning Rounds: 9 Stocks in Focus
Jim Cramer, the host of Mad Money, recently expressed his concerns about the uncertain economic outlook for 2025, particularly in relation to corporate earnings and the stock market's expectations for...
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on SRPT.
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Substack by Two Natural Capital. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.
12 High Growth Large Cap Stocks to Buy Now
BlackRock highlighted that its portfolio managers are broadly optimistic about US equities.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Call Transcript
Operator: Good day and welcome to the Sarepta Therapeutics Third Quarter 2024 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session.
8 Unstoppable Stocks That Could Make You Richer
In the current climate of extreme market volatility, finding safe and stable investments is challenging.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
Billionaire Hedge Funds
